Aim: This meta-analysis focuses on the current evidence of renal graft functioning and graft survival following early conversion to mTOR inhibitors with or without CNI in different randomised clinical studies.

Methods: We evaluated the current literature following PROSPERO approval CRD42016049410 describing the role of immunosuppressive agent, mTOR inhibitors as an alternative to Calcineurin Inhibitors (CNI) within six months of renal transplant by searching the PubMed, EMBASE, Cochrane, Crossref, and Scopus.

Results: The detailed analysis of all relevant literature performed for early CNI withdrawal i.e. within six months of renal transplant with subsequent introduction of mTOR-inhibitors. . .

Conclusions: The current evidences suggest that introduction of mTOR-inhibitors allows early and substantial CNI minimization. The mTOR inhibitors due to their complementary mechanism of action and favourable nephrotoxicity profile have opened the way for CNI reduction/withdrawal in the early post-transplant period. Howbeit, due to the higher rate rejection observed in these studies at 12 months, it is advisable not to offer these regimens to patients with moderate to high immunological risk though there was no significant difference in rejection at 36 months .

CITATION INFORMATION: Jayant K, Reccia I, Walton J, Sharma A, Halawa A. Systemic Meta-Analysis: Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? Am J Transplant. 2017;17 (suppl 3).

« Back to 2017 American Transplant Congress